bit messi color trajectori product concern
allergan report non-gaap dilut ep revenu compar
street estim respect though earli
launch anti-cgrp agent much impact botox chronic
migrain note overal botox sale growth moder
go forward given backdrop plu cautiou commentari
trajectori linzess along concern regard pipelin call
previous continu signific concern regard agn abil drive
meaning long-term ebitda compound-annual-growth-rate vein risk/reward profil share
ebitda favor view reiter neutral rate
slightli lower pt
brief color key driver ex-botox commentari linzess concern sale
ep neg impact recal ozurdex certain ex-u segment
vraylar surprisingli continu bright spot prescript show year-
to-dat growth rate per iqvia one concern linzess manag cite
low-singl digit growth go forward primarili due degrad net realiz price
botox migrain stand expect overal botox therapeut
growth moder mid-to-high singl digit therapeut indic
favor market dynam overact bladder one could interpret
commentari mean expect botox sale migrain flattish
declin dovetail check refer survey recent publish
pjc biotech team detail
thought go cite continu
commit core therapeut vertic gastroenterolog medic
aesthet eye care given myriad competit headwind near-term
competit anti-cgrp agent long-term competitor neuromodul
continu believ think expans
regard busi develop therapeut vertic instanc continu
larg gener practition gp sale presenc ineffici given
mainli focus linzess go matur isnt alreadi vein
realli need gp presenc realli gi presenc
well particularli relamorelin gastroparesi fail phase ii data mix
continu believ would behoov rethink gp presenc potenti
signific oper effici take aggress approach divestitur
 divest gi vertic explor therapeut vertic refer note
detail larger question whether senior leadership team
creativ reposit busi doubt
risk includ competit pressur key product
allergan focus brand across rang therapeut categori
intra-day price
dilut cash ep
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
consensu estim
compani report first call pjc estim
guidanc reflect restasi gener enter market current pjc estim reflect
gener competit start earli
compani report pjc estim
page
million except per shareactualspjc estimatesstreet estim gener net except per share guidanceguidanceestimatesadjust total revenu gross sg net interest expense/oth tax rate share ep exhibit
reflect restasi gener entrant ab-rat restasi gener earli
contribut botox hyperhidrosi includ botox see neuro urolog
consensu estim estim reflect restasi gener competit start
compani report first call pjc estim
slightli lower pt agn
new pt base price-to-earnings unchang ep estim
discount unchang one year unchang pt
impli ebitda multipl believ appropri context
multipl loss exclus competit headwind face botox therapeut
cosmet set late-stag pipelin myriad uncertainti abicipar
competit given rel high incid ocular inflamm seen current iter
product revis estim primarili reflect slightli lower contribut agn
medic aesthet busi primarili owe discount use drive coolsculpt
system placement lower contribut linzess owe pressur net realiz price
nod challeng associ payer landscap that dynam also neg
impact margin higher contribut vraylar driven continu strength volum
revis estim reflect year-over-year sale growth respect
page
million except per medic medic dermatolog neuro special central nervou women establish gener medicin intern world-wide product gener expens incom net
compani report pjc estim
page
fiscal year end decemb million except central nervou systemnamenda central nervou women lo women women establish establish establish gener medicin exhibit
begin began includ sale botox hyperhidrosi botox therapeut
compani report pjc estim
page
fiscal year end decemb million except medic aestheticsbotox fillers/juvederm regen medic medic medic dermatolog includ medic neuro urologybotox neuro neuro special allergan quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
cog product revenu
sale
expens total revenu
sell gener administr
sell gener administr
reflect restasi gener competit start earli
began report anda segment revenu discontinu oper start compani also report deduct repres product sold anda expect report deduct well
histor quarterli result pre may compar due divestitur anda segment
began report line item perform net incom begin metric calcul result chang
proprietari piper jaffray octob
current disclosur inform compani found
